Walvax Biotechnology Co., Ltd. (SHE:300142)
China flag China · Delayed Price · Currency is CNY
12.97
-0.04 (-0.31%)
Sep 16, 2026, 3:04 PM CST

Walvax Biotechnology Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
767.441,3533,7644,3653,8733,443
Short-Term Investments
421.81311.84----
Cash & Short-Term Investments
1,1891,6653,7644,3653,8733,443
Cash Growth
-58.22%-55.77%-13.77%12.68%12.49%75.54%
Accounts Receivable
2,0082,1452,4103,1013,5772,481
Other Receivables
120.674.4258.8114.18416.13774.86
Receivables
2,1292,2202,4683,2153,9933,255
Inventory
602.42574.16752.591,035995.81873.59
Other Current Assets
125.3687.7682.22119.2186.25107.94
Total Current Assets
4,0464,5467,0678,7338,9487,680
Property, Plant & Equipment
4,0024,0324,0793,7683,1612,604
Long-Term Investments
571.121,3671,6381,0571,2921,491
Goodwill
33.6633.6633.6633.6633.6633.66
Other Intangible Assets
834.28831.431,0351,0861,167434.98
Long-Term Accounts Receivable
-3.677.27---
Long-Term Deferred Tax Assets
107.12110.81104.56103.44124.84168.01
Long-Term Deferred Charges
636.09586.4513.86473.48309.381,022
Other Long-Term Assets
269.41559.32246.62333.54300.2240.63
Total Assets
10,50012,07114,72415,58915,33613,674

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
1,2791,3681,5681,8051,8361,258
Accrued Expenses
123.86212.79549.81722.051,145754.71
Short-Term Debt
336.8163.43-320.2797.18310
Current Portion of Long-Term Debt
67.147.6638.988.79--
Current Portion of Leases
50.611.477.8521.8823.354.6
Current Income Taxes Payable
3.822.71-14.1319.472.03
Current Unearned Revenue
25.5420.42106.18160.47192.9635.29
Other Current Liabilities
63.76150.6499.4151.25194.15870.61
Total Current Liabilities
1,9501,9372,3703,2043,5093,235
Long-Term Debt
836.26189.56433.34434.9314.24-
Long-Term Leases
7.8416.5211.7720.627.741.06
Long-Term Unearned Revenue
259.71276.77278.44423.33404.53344.3
Long-Term Deferred Tax Liabilities
13.2916.4255.9168.7190.9494.56
Other Long-Term Liabilities
101.1997.86742.08--
Total Liabilities
3,1692,5343,2164,1944,3463,675

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,5991,5991,5991,6071,6071,601
Additional Paid-In Capital
1,9193,4144,5494,9004,9654,772
Retained Earnings
3,4633,2243,1102,9842,5801,895
Treasury Stock
----358.63-286.42-
Comprehensive Income & Other
0.03384.29171.28217.18217.18216.33
Total Common Equity
6,9818,6219,4309,3499,0848,484
Minority Interest
350.24915.42,0782,0461,9061,515
Shareholders' Equity
7,3319,53611,50811,39510,9909,999
Total Liabilities & Equity
10,50012,07114,72415,58915,33613,674

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
1,299388.63491.94806.42462.51315.67
Net Cash (Debt)
-109.381,2763,2723,5583,4113,128
Net Cash Growth
--61.00%-8.05%4.31%9.06%62.77%
Net Cash Per Share
-0.070.802.052.222.131.99
Filing Date Shares Outstanding
1,5991,5991,5991,5991,6011,601
Total Common Shares Outstanding
1,5991,5991,5991,5991,6011,601
Working Capital
2,0952,6094,6975,5295,4404,445
Book Value Per Share
4.365.395.905.855.675.30
Tangible Book Value
6,1137,7568,3618,2307,8838,016
Tangible Book Value Per Share
3.824.855.235.154.925.01
Buildings
1,027954.86953.95948.5767.91541.68
Machinery
2,2722,2232,1962,0931,5801,235
Construction In Progress
2,2562,2842,1141,6451,5091,527